NEW YORK (GenomeWeb News) – Cancer Research UK, AstraZeneca, and Pfizer plan to launch a clinical trial that will screen for genetic markers to determine which of as many as 14 lung cancer drugs might work best for specific patients, CRUK said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.